Kronos Bio
New York, US · Founded 2017 · Delaware corporation · 15 known investors
Founders & leadership
NB
Norbert Bischofberger, Ph.D.Executive
CW
Christopher WilfongExecutive
Board
RB
Rebecka Belldegrun, M.D.Board director
OS
Otello Stampacchia, Ph.D.Board director
DM
AS
Arie S. Belldegrun, M.D.Board director
JA
JC
John C. Martin, Ph.D.Board director
Investors · 15
EcoR1 CapitalSan Francisco
GV (Google Ventures)Mountain View · $250K – $50M
Nextech InvestZurich · $648K – $3.2M
Vida VenturesLos Angelesvia Joshua Kazam · board
BlackRockreportedWilmington
Commodore CapitalreportedNew York
InvusreportedNew York
T. Rowe PricereportedBaltimore
Also in the syndicate · 7
Casdin PartnersFidelity Management and Research CompanyOmega FundsPerceptive AdvisorsleadPolaris PartnersSurveyor CapitalWoodline Partners
Reported raises · per SEC filings
Form D private placements$123M disclosed across 2 of 4 rounds · 2018–2020
▶$105MraisedJul 2019 · 50 investors · BiotechnologyRule 506(b)
▶$105MraisedJul 2019 · 50 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jacob LovenDirector
- Rebecka Belldegrun, M.D.Director
- Norbert Bischofberger, Ph.D.Executive Officer, Director
- John C. Martin, Ph.D.Director
- Philip GutryExecutive Officer
- David M. TanenExecutive Officer, Director, Promoter
- Sean AlgeoExecutive Officer
- Joshua A. KazamDirector
- Otello Stampacchia, Ph.D.Director
- Arie S. Belldegrun, M.D.Director
- Offering amount
- $105M
- Amount sold
- $105M
- Proceeds to insiders
- $360K
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$18MraisedJun 2018 · 32 investors · BiotechnologyRule 506(b)
▶$18MraisedJun 2018 · 32 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rebecka Belldegrun, M.D.Director
- Otello Stampacchia, Ph.D.Director
- David M. TanenExecutive Officer, Director, Promoter
- John C. Martin, Ph.D.Director
- Norbert Bischofberger, Ph.D.Executive Officer, Director
- Arie S. Belldegrun, M.D.Director
- Christopher WilfongExecutive Officer
- Joshua A. KazamDirector
- Offering amount
- $18M
- Amount sold
- $18M
- Proceeds to insiders
- $360K
- First sale
- May 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Kronos Bio went on to found or lead other companies.
Competitors · 4
by search overlapBioworld29 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
bio25 shared keywordsBIO is the world's largest advocacy association representing biotechnology companies and research institutions across the United States and 30+ other nations. The organization facilitates industry networking through events, conferences, and partnering software while providing cost-savings programs and advocacy services for member companies.
Northwest Biotherapeutics19 shared keywordsNW Bio develops personalized dendritic cell-based cancer vaccines intended to treat a range of solid tumor cancers as an alternative to chemotherapy. Its clinical-stage products target cancers including glioblastoma, inoperable solid tumors, ovarian cancer, and prostate cancer.
Belenosbio18 shared keywordsBelenos Biosciences develops long-acting bispecific antibody therapeutics for chronic inflammatory diseases such as COPD, asthma, atopic dermatitis, CRSwNP, and CSU. Its pipeline includes BEL512 (targeting TSLP and IL-13) and BEL536 (targeting OX40L and IL-13), both aimed at modulating type 2 inflammation.
Companies competing with Kronos Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- Who are Kronos Bio's investors?
- Kronos Bio's investors include EcoR1 Capital, GV (Google Ventures), Nextech Invest, Vida Ventures, BlackRock, Commodore Capital, Invus, T. Rowe Price.
- How much funding has Kronos Bio raised?
- Kronos Bio has disclosed $123M raised across 2 of its 4 known rounds.
- Where is Kronos Bio headquartered?
- Kronos Bio is headquartered in New York, US.